瑞格列奈治疗2型糖尿病的有效性及安全性的评价

目的评价瑞格列奈治疗2型糖尿病的有效性。方法采用随机对照双盲双模拟临床试验方法,一共收集70例2型糖尿病患者,采用随机分组的方法将患者分为试验组与对照组。试验组35例,口服国产瑞格列奈片1mg,1天3次;对照组35例,口服格列吡嗪片5mg,1天3次,经过2周的平衡期后进入治疗期,疗程12周。结果2组患者,与用药前比较,治疗12周,2组空腹血糖均下降,但无统计学意义;2组餐后血糖治疗后与治疗前相比,差异有统计学意义(P<0.05)。瑞格列奈组餐后1h胰岛素增加,与治疗前相比有统计学意义。结论瑞格列奈1mg,1天3次,与格列吡嗪5mg,1天3次比较降低空腹血糖疗效相当,均能显著降低餐后血糖。

Efficacy and safety of repaglinide tablet in type 2 diabetic patients

Objective] To evaluate the efficacy and safety of repaglinide tablet in comparision with glipizide in type 2 diabetic patients. Methods] Seventy type 2 diabetic patients were randomly assigned to the therapy group and the control group. The trial was consisted of 2 weeks equilibrated period followed by 12 week treatment course. Results] The mean fasting blood glucose in both groups decreased at week 12, but there was no statistically significant difference between 2 groups; The mean postprandial blood glucose reduced in therapy group and control group. There was statistically significant difference of postprandial blood glucose between 2 groups(P <0.05). Conclusions] The efficacy and safety repaglinide (120 mg, tid) equals to glipizide (5 mg, tid) in type 2 diabetes. Repaglinide can reduce postprandial blood glucose.